Wholesale Emtreo 5g for US Hospitals | Ernest Oncology India Supply

Emtreo 5g Injection: High-Dose Methotrexate for Advanced Oncology and Hematology

Are you searching for a reliable Emtreo 5G injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of critical care oncology medications. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that high-dose chemotherapy agents reach healthcare facilities with maximum integrity and efficient global logistics.

Detailed Product Overview: What is Emtreo 5g?

Emtreo 5g is a high-concentration intravenous injection containing 5 grams of Methotrexate. It is a cornerstone of systemic chemotherapy, classified as an antimetabolite and antifolate agent.

Manufactured by Emcure Pharmaceuticals, Emtreo 5g is designed for hospital settings requiring high-dose methotrexate (HDMTX) protocols. For international B2B procurement, Emtreo offers a world-class, cost-effective solution for treating aggressive malignancies, providing critical support for patients in complex clinical environments.

Primary Therapeutic Indications

Emtreo 5g Injection is clinically indicated for the following:

1. Osteosarcoma: High-dose protocols for the treatment of bone cancer.

2. Acute Lymphoblastic Leukemia (ALL): Used in maintenance and prophylaxis of meningeal leukemia.

3. Non-Hodgkin’s Lymphoma (NHL): Particularly aggressive types like Burkitt’s lymphoma.

4. Trophoblastic Diseases: Treatment of gestational choriocarcinoma.

5. Advanced Cancers: Also utilized in certain protocols for breast, lung, and head and neck cancers.

Mechanism of Action: How Emtreo 5g Works

Methotrexate, the active agent in Emtreo, disrupts the life cycle of rapidly dividing cancer cells:

• DHFR Inhibition: It competitively inhibits the enzyme dihydrofolate reductase (DHFR).

• DNA Synthesis Arrest: By blocking DHFR, it prevents the conversion of folic acid into its active form, tetrahydrofolate. This stops the production of thymidylate and purines, which are essential for DNA and RNA synthesis.

• S-Phase Specificity: Methotrexate is cell-cycle specific, primarily targeting the S-phase of cell division, effectively halting tumor growth and inducing cell death in cancerous tissues.

Administration and Safety Guidelines

• Professional Administration: Emtreo 5g must be administered via intravenous infusion only by qualified oncology staff.

• Hydration & Alkalinization: High-dose Methotrexate requires intensive pre- and post-hydration and urinary alkalinization to prevent renal toxicity.

• Leucovorin Rescue: HDMTX protocols invariably require Leucovorin (folinic acid) rescue to protect healthy cells from the lethal effects of the drug.

• Key Precautions:

  • Renal Function: Monitoring serum creatinine and methotrexate levels is mandatory.

  • Hepatotoxicity: Regular liver function tests (LFTs) are required.

  • Myelosuppression: Patients must be monitored for severe bone marrow depression.

  • Interactions: Avoid NSAIDs and penicillins during treatment, as they can decrease methotrexate clearance.

Why Source Emtreo 5g from Ernest Oncology?

• Strategic Indian Exporter: Authentic supply from Emcure Pharmaceuticals, ensuring 100% genuine products and competitive bulk pricing.

• Logistics Mastery: Expertise in navigating the specialized regulatory and customs landscapes of the USA, UK, Australia, and South Africa.

• Bulk Supply Reliability: We specialize in large-scale exports for government hospitals, oncology centers, and regional distributors.

• Quality Assurance: Every shipment is accompanied by a Certificate of Analysis (COA) and handled under strict GMP guidelines.